Concept Architecture
Concept
Theoretically, Clinical Benefit Rate (CBR) is a composite clinical outcome measure representing the proportion of patients who achieve a predefined beneficial response to treatment, typically comprising complete response, partial response and durable stable disease. It is widely used in oncology clinical trials to quantify overall treatment benefit beyond objective tumour shrinkage alone. The concept exists to capture meaningful disease control in situations where prolonged stable disease is considered clinically valuable.
Mathematically, Clinical Benefit Rate is expressed as the proportion of patients achieving complete response, partial response or stable disease maintained for a predefined minimum duration, usually specified within the study protocol. It is a descriptive proportion estimated from observed patient outcomes and is commonly accompanied by exact or asymptotic confidence intervals for statistical inference.
In practice, Clinical Benefit Rate is calculated from tumour response assessments performed using standard response criteria such as RECIST. Investigators classify each participant according to response status and calculate the proportion meeting the definition of clinical benefit. In health economics, CBR is frequently used as an intermediate effectiveness outcome when informing decision models, estimating treatment value and comparing oncology interventions, particularly where overall survival data remain immature.
Purpose
Used to quantify the proportion of patients achieving clinically meaningful disease control, supporting evaluation of treatment effectiveness and informing oncology health economic analyses.
Mathematical Formulae
Primary Formula
CBR = (CR + PR + SD) � N ? 100%
where SD represents stable disease maintained for the protocol-defined minimum duration.
Supporting Formulae
As a proportion:
CBR = (CR + PR + SD) � N
Standard error:
SE(CBR) = �(CBR ? (1 ? CBR) � N)
95% confidence interval (normal approximation):
CBR � 1.96 ? SE(CBR)
Related Mathematical Methods
- Objective Response Rate
- Disease Control Rate
- Binomial Proportion Estimation
- Confidence Interval Estimation
- Exact Binomial Methods
- Survival Analysis
Example
An oncology trial enrols 120 patients.
Complete response (CR) = 8
Partial response (PR) = 40
Stable disease lasting at least 24 weeks (SD) = 28
Clinical Benefit Rate:
CBR = (8 + 40 + 28) � 120 ? 100%
CBR = 76 � 120 ? 100%
CBR = 63.3%
Therefore, 63.3% of patients achieved clinical benefit according to the trial definition.
Excel Implementation
| Function | Example Formula | Health Economics Application |
|---|---|---|
| SUM | =SUM(CR,PR,SD) | Calculates the number of patients achieving clinical benefit. |
| COUNT | =COUNT(PatientRange) | Determines the total number of evaluable patients. |
| IF | =((CR+PR+SD)/N)*100 | Calculates the Clinical Benefit Rate. |
| SQRT | =SQRT((CBR*(1-CBR))/N) | Estimates the standard error of the proportion. |
| CONFIDENCE.NORM | =CONFIDENCE.NORM(0.05,SE,N) | Estimates the confidence interval for the Clinical Benefit Rate. |
VBA (Optional)
VBA can automate calculation of Clinical Benefit Rate, confidence intervals and subgroup analyses across oncology clinical trial datasets.
Sources
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer. 2009.
- FDA. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics.
- Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.
- Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes.
- Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation.
- CHEERS 2022 Statement.
Related Concepts (2)
Institutional Perspectives (1)
- HAS
Dual SMR/ASMR Rating Drives Reimbursement Rate and Price
HAS’s Transparency Committee gives each drug two clinical ratings rather than an ICER: the actual clinical benefit (Service Médical Rendu, SMR), which determines whether and at what rate the drug is reimbursed (15%, 30%, 65% or 100%; insufficient SMR = not reimbursed); and the improvement in clinical benefit versus existing treatments (Amélioration du Service Médical Rendu, ASMR, on a I–V scale from major therapeutic progress to no improvement), which guides the price negotiation with the CEPS. Formal cost-effectiveness (by the CEESP) enters only for high-impact products.
Haute Autorité de Santé, Transparency Committee doctrine (SMR / ASMR)View source →
Library
Publications
1
A Systematic Review of the Effectiveness of Adalimumab, Etanercept and Infliximab for the Treatment of Rheumatoid Arthritis in Adults and an Economic Evaluation of Their Cost-Effectiveness — Chen, Jobanputra, Barton, Jowett, Bryan, Clark, Fry-Smith & Burls, Vol. 10, No. 42 ed., 2006 (Health Technology Assessment (NIHR))
A landmark NIHR HTA monograph systematically reviewing the clinical effectiveness and modelling the cost-effectiveness of anti-TNF biologics (adalimumab, etanercept, infliximab) for rheumatoid arthritis using the Birmingham Rheumatoid Arthritis Model, an exemplar of HTA-body economic evaluation in a musculoskeletal disease.
Frequently Asked Questions (6)
What is the clinical benefit rate?
A cancer outcome measure combining complete response, partial response, and stable disease rates, giving a broader benefit picture than response rate alone.
Source: Eisenhauer et al. 2009
What broader benefit does the clinical benefit rate capture?
The clinical benefit rate captures a broader picture of a cancer treatment's benefit than a simple response rate, by counting both the patients whose tumours shrank and those whose disease held steady. It combines complete responses, partial responses, and stable disease into one figure, on the reasoning that keeping a cancer from growing is itself worthwhile, even without shrinkage. This wider measure suits treatments that stabilise rather than shrink tumours. Counting shrinkage and stability together is what it does. Eisenhauer and colleagues (2009) describe such measures.
Source: Eisenhauer et al. 2009
What does the clinical benefit rate combine?
The clinical benefit rate combines the rates of complete response, in which the cancer disappears; partial response, in which it shrinks; and stable disease, in which it neither grows nor shrinks significantly, into a single measure of benefit. So the clinical benefit rate combines responses and stable disease, which is why it is broader than response rate, since it includes both those whose cancer shrinks or disappears and those whose disease is stable, and combining these captures the patients who gain benefit through disease control, giving a fuller measure of a treatment's benefit than counting responses alone.
Source: Eisenhauer et al. 2009
How does the clinical benefit rate differ from response rate?
The clinical benefit rate differs from response rate in that it includes stable disease as well as complete and partial responses, whereas response rate counts only those whose cancer shrinks or disappears. So the clinical benefit rate is broader than response rate, which is why it includes stable disease, since it captures patients whose disease is controlled even without shrinking, and this broader measure gives a fuller picture of benefit than response rate alone, which is limited to responses, making the clinical benefit rate useful for reflecting benefit that includes disease stability as well as tumour shrinkage.
Source: Eisenhauer et al. 2009
Why is the clinical benefit rate used?
The clinical benefit rate is used to give a broader picture of a treatment's benefit by including stable disease alongside responses, capturing patients who benefit through disease control even without tumour shrinkage. So the clinical benefit rate is used for a fuller measure of benefit, which is why it includes stable disease, since some patients benefit from a treatment that stabilises their disease without shrinking it, and counting these alongside responses gives a more complete measure of benefit, making the clinical benefit rate useful where disease control, not only shrinkage, is a meaningful outcome of treatment.
Source: Eisenhauer et al. 2009
How does the clinical benefit rate relate to the disease control rate?
The clinical benefit rate relates to the disease control rate in that both combine complete response, partial response, and stable disease, capturing the proportion of patients whose disease is controlled, and the terms are closely related. So the clinical benefit rate and disease control rate are closely related measures, which is why they overlap, since both include responses and stable disease to capture benefit through disease control, and the two describe similar concepts of the proportion of patients benefiting through control of their disease, giving a broader picture than response rate alone by including stable disease alongside responses.
Source: Eisenhauer et al. 2009
Trust Record
Verified by Dr Darrin Baines
British health economist
Professional identity: darrinbaines.org
Verification date: 14 May 2026
Content version: 1.0.0
Canonical Identity
- Term code
- HE-PE-OO-005
Stable URI · Machine-readable · Resolvable · CC BY 4.0